Sinocare Showcases Digital Innovations at CMEF to Revolutionize Global Chronic Disease Management
In a remarkable exhibition at the 93rd China International Medical Equipment Fair (CMEF), Sinocare presented its latest advancements under the theme "Leading Digital Healthcare for Global Health." The company showcased its commitment to redefining chronic disease management through innovative technologies, integrated solutions, and strategic partnerships.
Sinocare's presentation highlighted an extensive digital ecosystem designed to adapt to modern healthcare needs. At the forefront was their proprietary third-generation biosensor technology, part of a continuous glucose monitoring (CGM) portfolio. These cutting-edge devices leverage artificial intelligence for predictive alerts, trend forecasting, and personalized interventions, allowing for real-time monitoring for up to 15 days. Notably, Sinocare is the first Chinese CGM brand certified under the CE-MDR, marking significant growth in Europe, Southeast Asia, and the Middle East.
Additionally, Sinocare unveiled a "Personal Palm Laboratory" test package that covers essential health markers such as glucose levels, blood pressure, uric acid, lipids, and ketones. With AI-supported data integration and automated risk alerts, these solutions enhance continuous, intelligent, and visualized home health management.
For primary care and clinical settings, Sinocare introduced integrated solutions, including non-invasive diabetes risk screening (AGEscan), portable multifunctional analyzers, and HbA1c systems. This range of tools enables standardized testing in community clinics, pharmacies, and health centers, boosting accessibility and supporting gradual health service delivery.
During CMEF, Sinocare also announced two significant partnerships to fortify its ecosystem approach. Collaborating with JD Health aims to create a closed-loop model that combines testing, repurchase, and long-term management. Meanwhile, partnering with Meituan Healthcare focuses on expanding access through multi-channel distribution and public health initiatives. These collaborations enhance Sinocare's competence in products, data, services, and channel management.
Sinocare shared insights on complete cyclic chronic disease management, from hospital to home and from monitoring to intervention. Their CGM-based data systems shift diabetes management from experience-based approaches to data-driven precision levels. Additionally, Sinocare introduced the MIT intensive intervention model, which integrates medical nutrition, intelligent monitoring, and behavioral support for structured disease reversal processes.
Today, Sinocare ranks among the four largest glucose meter manufacturers globally, serving over 25 million users across 187 countries. As part of its future strategy, the company aims to leverage artificial intelligence and biosensor technologies to usher in a new era of smart, precise, and lifecycle-focused chronic disease management worldwide.
Comprehensive Digital Health Services Ecosystem
Sinocare's presentation highlighted an extensive digital ecosystem designed to adapt to modern healthcare needs. At the forefront was their proprietary third-generation biosensor technology, part of a continuous glucose monitoring (CGM) portfolio. These cutting-edge devices leverage artificial intelligence for predictive alerts, trend forecasting, and personalized interventions, allowing for real-time monitoring for up to 15 days. Notably, Sinocare is the first Chinese CGM brand certified under the CE-MDR, marking significant growth in Europe, Southeast Asia, and the Middle East.
Additionally, Sinocare unveiled a "Personal Palm Laboratory" test package that covers essential health markers such as glucose levels, blood pressure, uric acid, lipids, and ketones. With AI-supported data integration and automated risk alerts, these solutions enhance continuous, intelligent, and visualized home health management.
For primary care and clinical settings, Sinocare introduced integrated solutions, including non-invasive diabetes risk screening (AGEscan), portable multifunctional analyzers, and HbA1c systems. This range of tools enables standardized testing in community clinics, pharmacies, and health centers, boosting accessibility and supporting gradual health service delivery.
Strategic Partnerships for Ecosystem Expansion
During CMEF, Sinocare also announced two significant partnerships to fortify its ecosystem approach. Collaborating with JD Health aims to create a closed-loop model that combines testing, repurchase, and long-term management. Meanwhile, partnering with Meituan Healthcare focuses on expanding access through multi-channel distribution and public health initiatives. These collaborations enhance Sinocare's competence in products, data, services, and channel management.
Global Influence from Chinese Leadership
Sinocare shared insights on complete cyclic chronic disease management, from hospital to home and from monitoring to intervention. Their CGM-based data systems shift diabetes management from experience-based approaches to data-driven precision levels. Additionally, Sinocare introduced the MIT intensive intervention model, which integrates medical nutrition, intelligent monitoring, and behavioral support for structured disease reversal processes.
Today, Sinocare ranks among the four largest glucose meter manufacturers globally, serving over 25 million users across 187 countries. As part of its future strategy, the company aims to leverage artificial intelligence and biosensor technologies to usher in a new era of smart, precise, and lifecycle-focused chronic disease management worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.